Related Experiment Videos
Assessment of coenzyme Q10 tolerability in Huntington's disease
1Department of Neurology, University of Rochester School of Medicine and Dentistry, New York, USA.
Insights
Coenzyme Q10 (CoQ) showed good tolerability in Huntington's disease (HD) patients over 6 months. While not significantly impacting clinical ratings, its safety profile supports further trials for HD progression.
Area of Science:
- Neuroscience
- Clinical Pharmacology
Background:
- Huntington's disease (HD) is a progressive neurodegenerative disorder with limited treatment options.
- Coenzyme Q10 (CoQ) is an antioxidant with potential neuroprotective properties.
Purpose of the Study:
- To evaluate the tolerability and efficacy of CoQ in patients with HD.
- To assess the safety and potential benefits of CoQ supplementation in HD management.
Main Methods:
- A 6-month open-label trial involving 10 HD patients.
- Clinical assessments included the HD Rating Scale (HDRS) and HD Functional Capacity Scale (HDFCS).
- Standardized neuropsychological tests and monthly adverse event monitoring were conducted.
Main Results:
- CoQ doses ranged from 600 to 1,200 mg/day.
- All participants completed the study; four reported mild adverse events (headache, heartburn, fatigue, increased involuntary movements).
- No significant changes were observed in clinical ratings (HDRS, HDFCS) or neuropsychological measures.
Conclusions:
- Coenzyme Q10 (CoQ) was well-tolerated in patients with Huntington's disease (HD) over a 6-month period.
- The favorable safety profile of CoQ suggests its suitability for further investigation in long-term clinical trials.
- Additional research is warranted to determine if CoQ can modify the progression of Huntington's disease.
Abstract:
We performed a 6-month open-label trial to evaluate the tolerability and efficacy of coenzyme Q10 (CoQ) in 10 patients with Huntington's disease (HD). Subjects were evaluated at baseline, 3 months, and 6 months using the HD Rating Scale (HDRS), the HD Functional Capacity Scale (HDFCS), and standardized neuropsychological measures. Adverse events (AEs) were assessed by telephone interview every month. CoQ doses ranged from 600 to 1,200 mg per day. All subjects completed the study, although four subjects reported mild AEs, including headache, heartburn, fatigue, and increased involuntary movements. There was no significant effect of the treatment on the clinical ratings. The good tolerability of CoQ suggests that it is a good candidate for evaluation in long-term clinical trials designed to slow the progression of HD.